329 POSTER Vorinostat significantly enhances the antitumor activity of temsirolimus in renal cancer

Steffan T. Nawrocki(University of Arizona), Jennifer S. Carew(University of Arizona), S. Smith, Kelli Oberheu(The University of Texas at San Antonio Health Science Center), Frances Giles, Jesús Esquivel(Saint Agnes Hospital), Alain C. Mita(Cedars-Sinai Medical Center), E. Ramírez Medina, M. Mita(Samueli Institute)
European Journal of Cancer Supplements
October 1, 2008
10.1016/s1359-6349(08)72263-8
Cited by 0

Related Papers

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance
|Blood|2007|485
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
|Cancer Letters|2008|426
Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells
|Cancer Research|2005|324
Targeting HSP90 for cancer therapy
|British Journal of Cancer|2009|320